Dr. Massimo Breccia is assistant physician at Sapienza University of Rome, Azienda Policlinico Umberto I. His scientific interests and publications as author or co-author (more than 300 papers in peer reviewed journals) are mainly focused on biological and clinical aspects of acute and chronic myeloid leukemias and myelodysplastic syndromes. He is a peer-reviewer for several journals such as Blood, Haematologica, Leukemia Research, British Journal of Haematology, etc and member of editorial board of 5 journal (Leukemia Research, Leukemia Research and Treatment, Hematology Reviews, etc).He is a member of SIE, SIES, EHA and participates as study coordinator in several clinical trials for CML, AML and MDS. He is secretary of GIMEMA QoL Working Party.

Terrence Burke received his Ph.D. in Medicinal Chemistry from the University of Washington (Seattle) and has spent most of his professional career within the Intramural Program of the National Institutes of Health (NIH). He is currently a Senior Investigator in the Chemical Biology Laboratory (National Cancer Institute). He has published more than 300 scientific publications and is a co-inventor on 20 issued U.S. patents.

Dr William Cho main research interests have been focusing on cancer studies to discover biomarkers for cancer diagnosis, treatment prediction and prognostication. He has published over 230 peer-reviewed papers (Lancet Oncology, Clinical Cancer Research, Clinical Chemistry, Annuals of Oncology, etc) covering cancer biomarkers, proteomics, microRNAs, Chinese medicine and plenty of books including "MicroRNAs in cancer translational research", "An omics perspective on cancer research", "Supportive cancer care with Chinese medicine", etc. These papers have received >7,000 citations. Dr Cho is also a grant reviewer of the Hope Funds for Cancer Research (USA), Cancer Research (UK), National Medical Research Council (Singapore), etc.

MD in 1966. Assistant Professor in 1966, Full Professor in 1975, and Professor Emeritus in 2012 at the University of Genoa (Italy). Director of the Institute of Hygiene and Preventive Medicine (1986-1998) and Department of Health Sciences (1999-2005, 2010-2012). Author of 465 full length papers, 310 of which available in PubMed, cited more than 14,000 times. He collaborated with 150 laboratories all over the world. Member of the editorial board of 16 international journals. Principal investigator in a number of research projects, 10 of which awarded by the US NIH/NCI. He received several awards, among which the honor from MSU (2002), the Sobels Award (2005), and dedication of ICMAA (Brazil, 2010).

Prof Ferguson obtained a D. Phil. (Oxon,) from the University of Oxford. On her return to New Zealand, she developed a linkage with some anticancer drug developer, who were developing the Auckland Cancer Society Research Centre, based the The University of Auckland, New Zealand. Lynnette had become interested in applying her genetics traning to an understanding of adverse genetic effects of novel drugs. She joined the Cancer Research Centre to set up the Centre for Mutagen Testing, which still functions to test anticancer drugs, novel pharmaceutical products and occupational situations as caner hazards in New Zealand. He rstudies on causes of cancer have led to a sugnificant amount of work on the New Zealand diet, and she maintains a dual interest in drugs and nutrients in the treatment and cause of cancer.

Dr. Grunt obtained a doctorate (Ph.D.) in Cell Biology from the University of Salzburg, Austria. Dr. Grunt also holds an Master of Science in Experimental Biology from the University of Salzburg.Currently Dr. Grunt is also an Associate Professor in the Medical University of Vienna, Austria. He has published more than 80 scientific publications and is a named inventor of several U.S patents.Dr. Grunt received several awards from the International Society of Differentiation (ISD), the Austrian Association of Clinical Oncology and from the Austrian Society of Hematology and Oncology. He is member of the American Association of Cancer Research (AACR), the European Association of Cancer Research (EACR), the International Society of Differentiation (ISD), the International Society of Cancer Metabolism (ISCaM), and the Union for International Cancer Control (UICC).

Professor Haber graduated with a PhD from the University of New South Wales, Australia, in the field of chemical carcinogenesis, and undertook post-doctoral positions at the Hadassah Hebrew University, Israel and the Albert Einstein College of Medicine, New York. She is Executive Director of Children’s Cancer Institute, and Head of the Institute’s Experimental Therapeutics Program and is internationally recognised for her world-class research into the treatment of neuroblastoma and acute lymphoblastic leukaemia in children. She has received numerous awards, particularly in terms of translating her research findings into the clinic, including the 2014 Cancer Institute NSW Premier’s Award for Outstanding Cancer Researcher of the Year and in 2015 was appointed an inaugural Fellow of the Australian Academy of Health and Medical Sciences. She has a long and continuous record of peer-reviewed grant funding and an excellent track record with more than 170 journal publications.

Chaunshu Huang is a Professor of Department of Environmental Medicine and Biochemistry and Molecular Pharmacology and Urology, and Deputy Director of Nelson Institute of Environmental medicine, New York University School of Medicine. Dr. Huang published more than 280 research papers with total citation over 11,200. Chuanshu’s major research addresses fundamental questions concerning the responses of mammalian cells to environmental carcinogens at the levels of protein kinases, transcription factors and their target genes, as well as protein modification both in vitro and in vivo. His research also includes elucidation of tumor invasion and metastasis, as well as screening and identifying novel anti-cancer drugs and the molecular mechanisms underlying their anti-cancer effect.

Dr. Hideki Kasuya obtained a MD from Aichi Medical University, and a PhD in Medicine from Nagoya University Graduate School of Medicine. He is holing tile of FACS (Faculty of American College of Surgery). He spent a time in Mass General Hospital (Dept. of Surgery, Boston) as research fellow. Currently Dr. Hideki Kasuya is a Professor in Cancer Immune therapy, International Center for Medical Technology in USA, and Chairman of Cancer Immune Therapy in Nagoya University Graduate School of Medicine in Japan. Dr. Hideki Kasuya is currently the Editorial Advisory Board member (Current Cancer Drug Targets), published by Bentham Science Publishers.

Dr. Keller obtained Doctor of Veterinary Medicine (D.V.M.) and Masters of Preventive Veterinary Medicine (M.P.V.M.) degrees from the University of California, Davis and a doctorate (Ph.D.) in Developmental Biology from the University of Wisconsin, Madison. Currently, Dr. Keller is a Professor in the Departments of Urology and Pathology at the University of Michigan. He has published more than 200 scientific publications.

Junya Kuroda, holder of M.D. and Ph.D. degrees, is an associate professor at the Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine in Kyoto, Japan, and has published more than 120 articles.Junya Kuroda’s research interests focused on the identification of the disease–specific dysregulation of epigenetics, genetics, cytogenetics, and cell signaling, to develop novel therapeutic strategies and biomarkers for cancers, especially hematologic malignancies, such as leukemias, lymphomas, or myeloma, while also covers clinical researches in hematological oncology.

Dr. Mu obtained his PhD degree in Chemistry from the University of California at Berkeley with Dr. Judith P. Klinman. Dr. Mu’s postdoctoral research on the topic of human nucleotide excision repair mechanism with Dr. Aziz Sancar at the University of North Carolina at Chapel Hill was cited by the 2015 Nobel Prize in Chemistry awarded to Dr. Aziz Sancar. At present, Dr. Mu is a Professor in the Eastern Virginia Medical School. He is currently on the Editorial Board of Scientific Reports (Nature Publishing Group) and Journal of Cytology and Molecular Biology (Avens Publishing).

Debabrata (Dev) Mukhopadhyay, Ph.D.: Professor of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Jacksonville, Florida, has a joint appointment with the Department of Physiology and Biomedical Engineering. Before moving to Mayo Clinic as Professor 14 years ago, he was research fellow and later independent investigator followed by as an Associate Professor at Harvard Medical School, Boston. He has been carried out angiogenesis and tumor microenvironment related research and also leading translational nanomedicine program including new drug delivery systems. He has been serving as reviewer for several study sections in NIH and agencies. Recently, he has been appointed as the Florida Department of Health Cancer Research Chair. He has published more than 190 peer-reviewed papers in different journals including Nature, Nature Medicine, Caner Cell, Cancer Research, Nano Letters. He has several patents and has been involved to develop different start up companies in the area of therapy and diagnosis of the diseases.

Dr. Franco Patrone MD obtained specialization degrees in General Medicine, Hematology, and Oncology from the University of Genova, Italy.Currently Dr. Patrone is an adjunct professor of Internal Medicine in the Departtment. of Internal Medicine, University of Genova. He has published more than 170 scientific publications reported on PubMed.Dr. Patrone has been, director of the first Medical Clinic and of the Department of Internal Medicine, University of Genoa, as well as of the Internal Medicine and Oncology Clinic and of the Department of Hematology and Oncology, San Martino University Hospital, Genoa, Italy.

Yves Pommier is the Chief of the Developmental Therapeutics Branch, NCI. He obtained his M.D. and Ph.D. from the University of Paris, and has studied DNA topoisomerases and the pharmacology of their inhibitors for the past 30 years. Three of his topoisomerase I inhibitors are in clinical trials. Dr. Pommier also discovered the first HIV-1 integrase inhibitors and the mechanism of action of poly(ADPribose) polymerase inhibitors by trapping PARP-DNA complexes. He pioneered the concept of drugs acting as interfacial inhibitors.

Dr. Prosperi graduated in Biological Sciences at the University of Pavia (Italy) and performed PhD studies in Physiological Sciences at the University of Milano, and in the Histochemistry Dept. of Leiden University” (Nederland). Dr. Prosperi is a Senior Researcher in the Institute of Molecular Genetics of the Italian National Research Council (CNR), lab of Genome Stability and DNA damage response, with more than 100 publications. Formerly, Lecturer in Physiopathology of the Cell Cycle, in the Medical Faculty of Pavia University, Dr. Prosperi is currently a teacher in the PhD program in “Genetics, Molecular and Cellular Biology” (Pavia University).

Dr. Daniel Raben received his PhD in Biochemistry from Washington University. Following a postdoctoral fellowship at the University of California-Irvine, he joined the faculty at The Johns Hopkins University School of Medicine. He has been there for over 30 years and is a Professor of Biological Chemistry, Physiology, and Oncology. He has a national and international reputation for his work the interfacial enzymology of lipid metabolizing enzymes and the role of these enzymes in the nervous system.

Balázs Sarkadi, MD, Ph.D., spent several years as a post-doc and then as a visiting scientist at major universities in the United States and Canada. He is research professor at Semmelweis University, member of the Hungarian Academy of Sciences, past president of FEBS, member of several international research societies including the Academia Europeae. His research has been focusing on membrane proteins, including the investigation of ABC membrane transporters, which play a major role in the multidrug resistance of cancer, in general pharmacology, and in stem cell function. He has published more than 250 papers in international scientific journals, with a citation number over 13,000.

Dr. Kalkunte Srivenugopal obtained his Ph.D. in Biochemistry From the Indian Institute of Science. He has been in the United States since 1981 and is currently a tenured Professor of Biomedical Sciences at the Texas Tech University School of Pharmacy in Amarillo, Texas, USA. Dr. Srivenugopal’s research interests include brain tumor chemotherapy, DNA repair, drug discovery, p53 biology and redox signaling. He has received funding from the National Institutes of Health, Cancer Prevention Research Institute of Texas and many private foundations. He has published more than 85 peer-reviewed articles.